
Drug developer Candel Therapeutics' CADL.O shares jump 5.4% to $4.92
CADL agrees to sell 3.2 million shares at $4.67 apiece in registered direct offering for gross proceeds of $15 million
Stock closed down 1.7% at $4.67 on Monday
Existing institutional investors and CADL executives took part in the offering
Proceeds will be used to support pre-commercialization and launch readiness activities for CAN-2409, its prostate cancer therapy
All 4 brokerages covering stock rate "buy" or higher; median PT $22 - data compiled by LSEG
As of last close, CADL stock down 46.2% YTD